ArticleJournal of inflammation research2025
Disulfidptosis-Related Genes as Novel Biomarkers and Therapeutic Targets in Dilated Cardiomyopathy.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Disulfidptosis: Mechanisms, evidence boundaries, and translational opportunities.Redox biology · 2026Review
- Disulfidptosis in heart failure: an emerging mechanism awaiting exploration.Frontiers in cardiovascular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dilated cardiomyopathy (DCM) is a severe cardiac condition characterized by ventricular dilation and impaired systolic function, leading to heart failure and sudden death. Current treatments have limited efficacy in reversing disease progression. Recent research suggests that disulfidptosis, a novel cell death mechanism, may play a role in DCM pathogenesis, though its specific involvement remains unclear. Methods: This study utilized multiple GEO datasets to analyze the expression of 24 disulfidptosis-related genes (DiGs) in DCM patients and healthy controls. Differential expression analysis and consensus clustering were used to classify DCM patients into subgroups based on DiGs expression profiles. A predictive model was constructed using four machine learning methods, and its performance was validated with independent datasets. A ceRNA regulatory network was established, and in vivo experiments were conducted using a DCM mouse model to validate key findings. Results: Nineteen DiGs were differentially expressed between DCM and controls. Consensus clustering divided DCM patients into two subtypes with distinct immune profiles. The support vector machine (SVM) model demonstrated superior diagnostic performance (AUC = 0.983), identifying ACTN4, MYH10, TLN1, DSTN, and NCKAP1 as core predictors. In vivo validation confirmed their expression changes in myocardial tissue. Single-cell RNA-seq further revealed increased fibroblast and macrophage infiltration in DCM, along with enrichment of fibrotic and immune pathways. Quercetin and resveratrol were predicted as potential drugs targeting these core genes. Conclusion: This study demonstrates that ACTN4, MYH10, TLN1, DSTN, and NCKAP1 play significant roles in the pathogenesis of DCM, influencing immune cell infiltration and metabolic homeostasis. Quercetin and resveratrol were identified as potential therapeutic agents, offering new directions for DCM treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.